These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32954245)

  • 1. Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program.
    Bleeker JS; Sumey CJ; Powell SF; Steen PD; Keppen MD; Lohr M; Thambi-Pillai T; Kurniali P; Mazurczak M; Gitau MM; Blanchard MJ; Nowak RK; McGraw S; Sticca R; Tuvin D; Timmerman G
    Surg Open Sci; 2020 Oct; 2(4):25-31. PubMed ID: 32954245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Trinh KV; Fischer DA; Gardner TB; Smith KD
    Front Oncol; 2020; 10():1461. PubMed ID: 33042792
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
    McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
    HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
    Scheufele F; Hartmann D; Friess H
    Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study.
    Parsonson AO; Connolly E; Lee M; Hruby G; Sandroussi C; Merrett N; Samra J; Mittal A; Tse R; Grimison P
    ANZ J Surg; 2021 Nov; 91(11):2447-2452. PubMed ID: 34427029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.
    Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L
    Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
    Peng JS; Morris-Stiff G; Ali NS; Wey J; Chalikonda S; El-Hayek KM; Walsh RM
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):74-79. PubMed ID: 32861576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
    Wang G; Zhou D
    Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.
    Dholakia AS; Hacker-Prietz A; Wild AT; Raman SP; Wood LD; Huang P; Laheru DA; Zheng L; De Jesus-Acosta A; Le DT; Schulick R; Edil B; Ellsworth S; Pawlik TM; Iacobuzio-Donahue CA; Hruban RH; Cameron JL; Fishman EK; Wolfgang CL; Herman JM
    J Radiat Oncol; 2013 Dec; 2(4):413-425. PubMed ID: 25755849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.